561 related articles for article (PubMed ID: 34090959)
41. Treatment of alopecia areata of the beard with baricitinib.
Moussa A; Eisman S; Sinclair RD; Bhoyrul B
J Am Acad Dermatol; 2023 Apr; 88(4):948-950. PubMed ID: 36427662
[No Abstract] [Full Text] [Related]
42. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
Ismail FF; Sinclair R
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
[No Abstract] [Full Text] [Related]
43. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
Song CJ; Riley CA; Wilkison BD; Cho S
Mil Med; 2024 Jun; ():. PubMed ID: 38850223
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
[TBL] [Abstract][Full Text] [Related]
45. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
De Greef A; Thirion R; Ghislain PD; Baeck M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2869-2877. PubMed ID: 37717224
[TBL] [Abstract][Full Text] [Related]
46. Baricitinib in Alopecia Areata.
Messenger A; Harries M
N Engl J Med; 2022 May; 386(18):1751-1752. PubMed ID: 35507486
[No Abstract] [Full Text] [Related]
47. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
48. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
Piraccini BM; Ohyama M; Craiglow B; Bewley A; Ding Y; Chen YF; Dutronc Y; Pierce E; Durand F; Mostaghimi A
J Dermatolog Treat; 2023 Dec; 34(1):2227299. PubMed ID: 37381691
[TBL] [Abstract][Full Text] [Related]
49. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
50. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
51. Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.
Fang H; Zhang F; Lin W; Jiang Y; Liu Q; Yang D
Front Immunol; 2024; 15():1395288. PubMed ID: 38903518
[TBL] [Abstract][Full Text] [Related]
52. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.
Senna MM; Kwon O; Piraccini BM; Sinclair R; Ball S; Ding Y; Chen YF; Dutronc Y; King B
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3209-3220. PubMed ID: 37991697
[TBL] [Abstract][Full Text] [Related]
53. Emerging drugs for the treatment of alopecia areata.
Ramírez-Marín HA; Tosti A
Expert Opin Emerg Drugs; 2022 Dec; 27(4):379-387. PubMed ID: 36408593
[TBL] [Abstract][Full Text] [Related]
54. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
55. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
56. Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials.
Amer BE; Afifi E; Mouffokes A; Hamad AA; Amin AM; Abdelwahab OA
Clin Rheumatol; 2024 Feb; 43(2):579-589. PubMed ID: 37581759
[TBL] [Abstract][Full Text] [Related]
57. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
58. Emerging drugs for alopecia areata: JAK inhibitors.
Iorizzo M; Tosti A
Expert Opin Emerg Drugs; 2018 Mar; 23(1):77-81. PubMed ID: 29466675
[TBL] [Abstract][Full Text] [Related]
59. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
[TBL] [Abstract][Full Text] [Related]
60. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]